Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Allergan has reported revenues of $1.31bn for the fourth quarter ended 31 December 2010, compared to $1.22bn for the same period in 2009.
Subscribe to our email newsletter
For the fourth quarter of 2010, the company posted an operating income of $367.4m, compared to $316.9m for the same period in 2009.
For the full year ended 31 December 2010, Allergan has posted revenues of $4.92bn, compared to $4.5bn for the same period in 2009.
The company’s operating income was $258.6m, compared to $928m for the same period in 2009.
For the full year of 2011, Allergan expects total product net sales between $5,020m and $5,220m.
Allergan chairman of the board and CEO David Pyott said they are very pleased with our fourth quarter and full year results, as well as the record number of regulatory approvals secured in 2010. In 2011, they look forward to marketing the new products and therapies approved in 2010, as well as investing in R&D to reload our pipeline.